CharlesWilliamsFlexnerMD
Infectious Disease • Baltimore, MDProfessor of Medicine, Johns Hopkins University School of Medicine; Director, AIDS Clinical Trials Unit; Deputy Director, Institute for Clinical and Translational Research
Dr. Flexner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287Phone+1 410-955-5000Fax+1 410-955-5001
Summary
- Dr. Charles Flexner is an infectious disease specialist based in Baltimore, MD. He completed his medical education at Johns Hopkins University School of Medicine, followed by a residency in Internal Medicine at Stanford Health Care and fellowships in Infectious Disease at the National Institutes of Health Clinical Center and Johns Hopkins University. He is experienced in emerging infectious diseases and has published on topics such as the effectiveness of double-dose dolutegravir in tuberculosis treatment and long-acting antiretroviral therapies. Dr. Flexner has also been involved in several clinical trials, including studies on contraceptive implants, hepatitis C virus treatment, and HIV treatment regimens. He is the founding director of the Long-Acting/Extended-Release Antiretroviral Research Resource Program (LEAP), www.longactinghiv.org.
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 1988 - 1989
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1985 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1982 - 1985- Johns Hopkins University School of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1983 - Present
MD State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
- A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
- Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
- Join now to see all
Publications & Presentations
PubMed
- Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries.N Sarita Shah, Cissy Kityo, Michael D Hughes, Caitlyn McCarthy, Carole L Wallis
Clinical Infectious Diseases. 2025-02-05 - Investigations of Long-Acting Formulations in Children, Adolescents, and Pregnant Women: A Systematic Review.Lynn Bertagnolli, Zhengyi Deng, Melissa Davy-Rothwell, Elaine J Abrams, Charles Flexner
Pharmaceutics. 2025-01-15 - Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and Aging.Abigail Baim-Lance, Sarah Cooley, Moka Yoo-Jeong, Beau Ances, Gustavo Duque
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2024-12-11
Journal Articles
- Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-ChloroquineCharles Flexner, Michael M Lederman, Theresa A Shapiro, Clinical Infectious Diseases
Lectures
- Modern HIV Therapy: Progress and ProspectsVirology Education B.V, Baltimore, Maryland - 11/5/2012
Other
- Modern HIV Therapy: Progress and ProspectsCharles Flexner, MD, Clinical Pharmacology & Therapeutics
https://www.doximity.com/articles/d00fecdd-81cc-4143-b68b-e4c067729426
UpToDate, Wolters Kluwer Health - 2012-08-16
Press Mentions
Management of Patients with HIV, Limited Treatment OptionsOctober 26th, 2022- New Approaches to HIV Prevention, Management of Patients with HIVOctober 25th, 2022
- Forty Years on, Black Americans Disproportionately Hit by HIVMay 6th, 2021
- Join now to see all
Grant Support
- Johns Hopkins AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
- ACTG A5128National Center For Research Resources2005–2007
- ACTG A5191National Center For Research Resources2004–2007
- ACTG A5001National Center For Research Resources2004–2007
- ACTG 362National Center For Research Resources2004–2007
- ACTG A5223National Center For Research Resources2006
- Johns Hopkins Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2001–2006
- Oral ClotrimazoleNational Center For Research Resources2004–2005
- Interaction Of Amprenavir (Apv), Lopinavir (Lpv/R), And Efavirenz (EFV)National Center For Research Resources2004–2005
- ACTG Screening ConsentNational Center For Research Resources2004–2005
- ACTG 5077: Virologic StudiesNational Center For Research Resources2004–2005
- Antiretroviral Response To Idv/Rtv Containing Regimen In Hiv-Infected SubjectsNational Center For Research Resources2004
- ACTG A5043National Center For Research Resources2004
- ACTG 384National Center For Research Resources2004
- ACTG 372National Center For Research Resources2004
- A5058s: Augmentation Of Hiv-Specific Helper And CTL Response Through TherapeuticNational Center For Research Resources2004
- Trial Of Hydroxyurea In Combo With Antivirals In HIVNational Center For Research Resources2000–2002
- Trial Of Efv/Nfv In Combo With Zdv/3tc/Idv In AIDSNational Center For Research Resources2000–2002
- Protease/Nonnucleoside Transcriptase/Nucleoside HIV TherNational Center For Research Resources2000–2002
- Pharmacokinetic Action--Protease Inhibitors &AntilipidsNational Center For Research Resources2000–2002
- Nelfinavir Induced Diarrhea--Secretory VS NonsecretoryNational Center For Research Resources2000–2002
- HIV Protease Inhibitor &Methadone Metabolism In HIVNational Center For Research Resources2000–2002
- Fluconazole VS Episodic In HIV+ PTS With CandidiasisNational Center For Research Resources2000–2002
- Blood Lymphocytes From Hiv--Coreceptor Virus IsolationNational Center For Research Resources2000–2002
- Amprenavir In Combo With Abacavir/Efavirenz/AdefovirNational Center For Research Resources2000–2002
- ACTG 892--Antiretroviral Therapy Effects On Lean BodyNational Center For Research Resources2000–2002
- ACTG 365--Pharmacokinetics On Indinavir And RifabutinNational Center For Research Resources2000–2002
- Safety And Efficacy Of Ritonavir In Combination With Nelfinavir In HIVNational Center For Research Resources1998–2002
- Safety And Antiretroviral Activity Of Hydroxurea And DidanosineNational Center For Research Resources1998–2002
- ACT 307--Safety/Antiretrovirl Activity Of Hydroxyurea Alone/Combination With DDINational Center For Research Resources1998–2002
- ACTG 307 Dosing Study--Safety &Antiretroviral Activity Of HydroxyureaNational Center For Research Resources1999
- Preliminary Antiviral Activity Study Of GEM 91 Administered To HIV+ SubjectsNational Center For Research Resources1998–1999
- Phase I/II Multiple Dose Study Of GEM 91 Continuous IV Infusion In HIV+ PatientsNational Center For Research Resources1998–1999
- Phase I/II Protocol To Evaluate Electroinserted Rbc-Rcd4 In HIV SubjectsNational Center For Research Resources1997–1999
- Rifabutin And Ethambutol Effects On Clarithromycin PharmacokineticsNational Center For Research Resources1997
- Pharmacokinetics &Preliminary Antiviral Activity Study Of GEM 91National Center For Research Resources1997
Other Languages
- Italian
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/charles-flexner
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
